Approvedregulatory verdict

Evidence outlook

Approved: Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration, Diabetic Macular Edema

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (5)
US
  • Macular Edema Following Retinal Vein Occlusion (RVO)Outside this platform's coverage
  • Diabetic Retinopathy (DR)
  • Myopic Choroidal Neovascularization (mCNV)Outside this platform's coverage
Product first approved 2006FDA label
JP
  • Treatment of age-related macular degeneration with concurrent choroidal neovascularization
Product first approved 2009PMDA
EU
  • Lucentis is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to choroidal neovascularisation (CNV) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
Product first approved 2007EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (76)
Age-Related Macular Degeneration
NCT04667039 · AO GENERIUM
2022-03-20 – 2024-09-15 · Age Related Macular Degeneration (ARMD)
What this study did
NCT01748292 · Charles C Wykoff, PhD, MD
2012-12 – 2017-02 · Macular Degeneration
What this study did
NCT01948830 · Novartis Pharmaceuticals
2013-12-17 – 2015-11-19 · Age-related Macular Degeneration, Choroidal Neovascularization
What this study did
NCT02032173 · Novartis Pharmaceuticals
2014-05-19 – 2015-04-29 · Macular Edema, Macular Degeneration, Diabetes
What this study did
NCT00593450 · University of Pennsylvania
2008-02 – 2015-04 · Age Related Macular Degeneration
What this study did
NCT01255774 · The New York Eye & Ear Infirmary
2007-06 – 2012-12 · Age Related Macular Degeneration
What this study did
NCT01014468 · Instituto de Olhos de Goiania
2009-03 – 2012-02 · Age Related Macular Degeneration
What this study did
NCT00710229 · The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
2008-07 – 2011-12 · Age Related Macular Degeneration
What this study did
NCT01570608 · The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
2007-03 – 2011-08 · Age Related Macular Degeneration
What this study did
NCT00469352 · Oregon Health and Science University
2007-05 – 2010-04 · Macular Degeneration
What this study did
NCT00470678 · Novartis
2007-06 – 2008-11 · Choroidal Neovascularization, Age-Related Macular Degeneration
What this study did
NCT00331864 · Novartis
2006-04 – 2008-04 · Age Related Macular Degeneration, Choroidal Neovascularization
What this study did
NCT00275821 · Novartis
2005-12 – 2008-01 · Age Related Macular Degeneration
What this study did
NCT00251459 · Genentech, Inc.
2005-11 – 2007-09 · Choroidal Neovascularization, Age-related Macular Degeneration
What this study did
NCT00090623 · Genentech, Inc.
2004-08 – 2007-03 · Macular Degeneration
What this study did
NCT00061594 · Genentech, Inc.
2003-05 – 2006-09 · Macular Degeneration
What this study did
Diabetic Macular Edema
NCT05271539 · Cairo University
2020-07-01 – 2021-09-15 · Diabetic Macular Edema
What this study did
NCT04063358 · Second Military Medical University
2019-08-22 – 2021-08-31 · Diabetic Macular Edema, Cataract
What this study did
NCT02262260 · Novartis Pharmaceuticals
2014-12-12 – 2017-09-12 · Diabetic Macular Edema
What this study did
NCT02259088 · Novartis Pharmaceuticals
2014-11-05 – 2017-01-17 · Diabetic Macular Edema, Visual Impairment
What this study did
NCT00444600 · Jaeb Center for Health Research
2007-03 – 2014-02 · Diabetic Retinopathy, Diabetic Macular Edema
What this study did
NCT01661946 · Queen's University
2012-08 – 2013-08 · Diabetic Macular Edema
What this study did
NCT01135914 · Novartis Pharmaceuticals
2010-07 – 2013-03 · Diabetic Macular Edema
What this study did
NCT00989989 · Novartis
2009-09 – 2011-08 · Diabetic Macular Edema
What this study did
NCT01131585 · Novartis Pharmaceuticals
2010-06 – 2011-07 · Visual Impairment Due to Diabetic Macular Edema
What this study did
NCT00445003 · Jaeb Center for Health Research
2007-03 – 2010-07 · Proliferative Diabetic Retinopathy, Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT04757610 · Opthea Limited
2021-03-12 – 2025-03-31 · Neovascular Age-related Macular Degeneration
What this study did
NCT02243878 · King's College Hospital NHS Trust
2014-12 – 2024-04 · Neovascular (Wet) Age-related Macular Degeneration (AMD)
What this study did
NCT02611778 · Bioeq GmbH
2015-12-19 – 2018-06-06 · Age-related Macular Degeneration (AMD)
What this study did
NCT01780935 · Novartis Pharmaceuticals
2013-06-03 – 2015-07-09 · Neovascular Age-related Macular Degeneration
What this study did
NCT00891735 · Genentech, Inc.
2009-07 – 2012-08 · Age-related Macular Degeneration
What this study did
NCT00826371 · Novartis Pharmaceuticals
2009-01 – 2010-07 · Age Related Macular Degeneration
What this study did
NCT00599222 · Anders Kvanta
2008-02 – 2010-02 · Neovascular Age-related Macular Degeneration
What this study did
NCT00967213 · Novartis Korea Ltd.
2006-08 – 2008-02 · Neovascular Age-related Macular Degeneration
What this study did
Other / comorbidity
NCT05138029 · Affiliated Hospital of Nantong University
2021-11-15 – 2024-05 · Diabetic Retinopathy
What this study did
NCT05701124 · Zagazig University
2020-11-20 – 2022-11-20 · Retina Disease, Retinopathy of Prematurity, Ranibizumab
What this study did
NCT05033106 · Zagazig University
2020-09-01 – 2022-09-01 · Retinopathy of Prematurity Both Eyes
What this study did
NCT02640664 · Novartis Pharmaceuticals
2016-06-16 – 2022-04-21 · Retinopathy of Prematurity (ROP)
What this study did
NCT02623426 · JHSPH Center for Clinical Trials
2017-03-09 – 2022-02-02 · Uveitis, Macular Edema
What this study did
NCT02447185 · JUNYAN ZHANG
2015-06 – 2021-12 · Proliferative Diabetic Retinopathy
What this study did
NCT03452657 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2018-04 – 2020-06 · Diabetic Retinopathy, Ranibizumab
What this study did
NCT03203447 · Clearside Biomedical, Inc.
2018-03-05 – 2018-12-18 · Macular Edema, Retinal Vein Occlusion
What this study did
NCT02914626 · LEANDRO CABRAL ZACHARIAS
2016-10 – 2018-10 · Glaucoma, Neovascular, Ranibizumab
What this study did
NCT01489189 · Jaeb Center for Health Research
2012-03 – 2018-02-05 · Proliferative Diabetic Retinopathy
What this study did
NCT02375971 · Novartis Pharmaceuticals
2015-12-30 – 2017-12-14 · Retinopathy of Prematurity
What this study did
Phase 2/3 (19)
Age-Related Macular Degeneration
NCT02296567 · East Florida Eye Institute
2014-12 – 2016-07 · Age Related Macular Degeneration
What this study did
NCT01402544 · University of California, San Diego
2011-07 – 2015-03 · Age-Related Macular Degeneration
What this study did
NCT00590694 · Pacific Eye Associates
2006-10 – 2009-12 · Age-related Macular Degeneration, Pigment Epithelial Detachment, Neovascular Macular Degeneration, Wet Macular Degeneration
What this study did
Diabetic Macular Edema
NCT03784443 · Imperial College London
2019-09-01 – 2023-09-01 · Diabetic Macular Edema, Diabetes
What this study did
NCT01635790 · Prof. dr. R.O. Schlingemann
2012-06 – 2016-06 · Diabetic Macular Edema
What this study did
NCT00885794 · The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
2008-05 – 2012-05 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT00764738 · Retina Macula Institute
2008-10 – 2011-11 · Neovascular Age Related Macular Degeneration
What this study did
Other / comorbidity
NCT04460001 · Assiut University
2019-05-16 – 2021-12-01 · Ophthalmopathy
What this study did
NCT02769169 · Sun Yat-sen University
2018-08-01 – 2018-12-15 · Polypoidal Choroidal Vasculopathy
What this study did
NCT02328118 · JUNYAN ZHANG
2015-02 – 2017-05 · Proliferative Diabetic Retinopathy
What this study did
NCT01635803 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2012-06 – 2016-06 · Retinal Vein Occlusion
What this study did
NCT01030770 · King's College Hospital NHS Trust
2010-07 – 2016-05 · Diabetes Complications
What this study did
NCT02342392 · Universiti Sains Malaysia
2012-09 – 2014-09 · Pterygium
What this study did
NCT00996437 · Jaeb Center for Health Research
2010-06 – 2013-01 · Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
What this study did
NCT00811200 · Leiden University Medical Center
2009-09 – 2012-01 · Uveal Melanoma
What this study did
NCT00626782 · Wills Eye
2008-01 – 2011-04 · Glaucoma
What this study did
NCT00384449 · Oregon Health and Science University
2006-10 – 2009-04 · Eales' Disease
What this study did
NCT00930189 · Asociación para Evitar la Ceguera en México
2006-04 – 2006-09 · Subfoveal Choroidal Neovascularization
What this study did
Phase 2 (69)
Age-Related Macular Degeneration
NCT03071055 · Southeast Clinical Research Associates, LLC
2017-10-01 – 2019-06-03 · Exudative Age Related Macular Degeneration
What this study did
NCT02067013 · California Retina Consultants
2015-07 – 2017-07 · Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma
What this study did
NCT02387957 · Ophthotech Corporation
2016-04-26 – 2017-01 · Age-Related Macular Degeneration
What this study did
NCT01914159 · University Hospital, Bonn
2013-02 – 2016-03 · Age Related Macular Degeneration
What this study did
NCT01414153 · Lpath, Inc.
2012-08 – 2015-06 · Exudative Age-related Macular Degeneration
What this study did
NCT01243086 · McMaster University
2011-03 – 2015-05 · Wet Macular Degeneration
What this study did
NCT00931489 · Lawrence S. Morse, MD
2009-08 – 2014-06 · Age Related Macular Degeneration
What this study did
NCT00896779 · Steven R. Sanislo
2009-10 – 2013-09 · Macular Degeneration
What this study did
NCT01189019 · Anne Fung MD
2010-08 – 2013-03 · Wet Macular Degeneration, Macular Degeneration, Retinal Pigment Epithelial Detachment
What this study did
NCT01249937 · University Health Network, Toronto
2011-01 – 2011-10 · Wet Macular Degeneration
What this study did
NCT00713518 · Quark Pharmaceuticals
2009-11 – 2011-07 · Age Related Macular Degeneration
What this study did
NCT01122511 · Allergan
2010-08 – 2011-05 · Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
What this study did
NCT00492284 · QLT Inc.
2007-07 – 2010-05 · Choroidal Neovascularization, Macular Degeneration
What this study did
NCT00766337 · Santen Inc.
2008-12 – 2010-03 · Age-Related Macular Degeneration, Choroidal Neovascularization
What this study did
NCT00527475 · Texas Retina Associates
2007-05 – 2010-01 · Macular Degeneration
What this study did
NCT00390208 · Bay Area Retina Associates
2006-08 – 2009-12 · Age Related Macular Degeneration
What this study did
NCT00457678 · Vitreous -Retina- Macula Consultants of New York
2007-01 – 2007-12-04 · Age Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT02363621 · Arshad Khanani
2015-01 – 2017-10 · Diabetic Macular Edema
What this study did
NCT02127684 · Maturi, Raj K., M.D., P.C.
est. completion 2015-11 · Persistent Diabetic Macular Edema
What this study did
NCT02349516 · Starr Muscle
2015-02 – 2015-09 · Diabetic Retinopathy
What this study did
NCT01610557 · National Eye Institute (NEI)
2012-05 – 2015-02 · Diabetic Macular Edema
What this study did
NCT01823965 · Poitiers University Hospital
2011-10 – 2014-07 · Diabetic Macular Edema
What this study did
NCT01112085 · Especialistas en Retina Medica y Quirurgica Grupo de Investigacion
2010-04 – 2014-06 · Diabetic Macular Edema
What this study did
NCT01472510 · Vitreo-Retinal Associates, PC
2011-12 – 2014-01 · Diabetic Macular Edema
What this study did
NCT01445899 · Quark Pharmaceuticals
2012-02 – 2013-11 · Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
What this study did
NCT01077401 · Johns Hopkins University
2010-02 – 2013-03 · Diabetic Macular Edema
What this study did
NCT01487629 · University of Sao Paulo
2010-04 – 2012-09 · Diabetic Retinopathy, Macular Edema
What this study did
NCT00901186 · Novartis Pharmaceuticals
2009-11 – 2012-08 · Diabetic Macular Edema, Visual Impairment
What this study did
NCT01253694 · New England Retina Associates
2011-03 – 2012-07 · Diabetic Macular Edema
What this study did
NCT00815360 · Retina Associates of Florida, P.A.
2008-02 – 2011-08 · Diabetic Macular Edema
What this study did
NCT00407381 · Johns Hopkins University
2006-12 – 2011-08 · Diabetic Macular Edema
What this study did
NCT00387582 · Rocky Mountain Retina Consultants
2006-07 – 2009-02 · Diabetic Retinopathy, Diabetic Macular Edema
What this study did
NCT00284050 · Novartis
2005-10 – 2008-06 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT03423823 · Kapil Kapoor
2017-07-07 – 2020-06-26 · Wet Macular Degeneration, Wet Age-related Macular Degeneration
What this study did
NCT03362190 · Ophthotech Corporation
2017-10-11 – 2018-10-18 · Neovascular Age-related Macular Degeneration
What this study did
NCT05571267 · IVERIC bio, Inc.
2016-10-20 – 2018-04-24 · Neovascular Age-Related Macular Degeneration
What this study did
NCT02511613 · Ohr Pharmaceutical Inc.
2015-07 – 2016-04 · Age-Related Macular Degeneration
What this study did
NCT01089517 · Ophthotech Corporation
2010-03 – 2012-06 · Age-Related Macular Degeneration
What this study did
NCT00775411 · Allergan
2008-11 – 2010-04 · Choroidal Neovascularization, Age-Related Maculopathy
What this study did
NCT00373659 · University of Miami
2004-08 – 2007-06 · Neovascular Age-related Macular Degeneration
What this study did
NCT00344227 · University of Miami
2004-08 – 2007-04 · Neovascular Age-Related Macular Degeneration
What this study did
Other / comorbidity
NCT04667910 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2021-01-27 – 2022-11-16 · Central Retinal Vein Occlusion
What this study did
NCT04667897 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2021-01-28 – 2022-07-13 · Branch Retinal Vein Occlusion
What this study did
NCT03763227 · Sultan Qaboos University
2015-07-24 – 2019-08-29 · Retinal Dystrophies
What this study did
NCT02134457 · University Hospital Freiburg
2014-08 – 2017-01 · Retinopathy of Prematurity (ROP)
What this study did
Phase 1/2 (41)
Age-Related Macular Degeneration
NCT02140151 · Southern California Desert Retina Consultants, MC
2014-09-17 – 2020-07-09 · Age-related Macular Degeneration
What this study did
NCT02302989 · Leonard Feiner, MD, PhD
2015-05 – 2018-07 · Age-related Macular Degeneration
What this study did
NCT01674569 · Tyrogenex
2012-10 – 2015-02 · Exudative Macular Degeneration
What this study did
NCT02118831 · California Retina Consultants
2012-03 – 2014-04 · Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
What this study did
NCT00570193 · Mid-Atlantic Retina Consultations, Inc.
2006-12 – 2011-06 · Choroidal Neovascularization, Macular Degeneration
What this study did
NCT00284089 · Novartis
2005-04 – 2009-01 · Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)
What this study did
NCT00395707 · The National Retina Institute
2005-08 – 2008-04 · Macular Degeneration
What this study did
NCT00467935 · Retina Research Foundation
2007-03 – 2007-11 · Macular Degeneration
What this study did
NCT00056823 · Genentech, Inc.
2003-03 – 2005-12 · Age-Related Maculopathy
What this study did
Diabetic Macular Edema
NCT03973138 · Sun Yat-sen University
2015-01-01 – 2020-01-01 · Diabetic Macular Edema
What this study did
NCT02448446 · South Coast Retina Center; Carson, McBeath, Boswell, Inc.
2015-08 – 2018-05 · Diabetic Macular Edema, Hard Lipid Exudates
What this study did
NCT01934556 · Palmetto Retina Center, LLC
2013-11 – 2018-04 · Diabetic Macular Edema
What this study did
NCT01982435 · Justis Ehlers
2014-06-24 – 2016-05-26 · Diabetic Macular Edema
What this study did
NCT01845844 · Southeast Retina Center, Georgia
2013-04 – 2015-01 · Diabetic Macular Edema
What this study did
NCT01292798 · California Retina Consultants
2011-03 – 2013-04 · Diabetic Macular Edema
What this study did
NCT00440609 · Philip J. ferrone, M.D.
2007-03 – 2012-12 · Clinically Significant Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT01972763 · Northern California Retina Vitreous Associates
2013-10 – 2018-07 · Recalcitrant Wet Age-related Macular Degeneration
What this study did
NCT01926977 · Arshad Khanani
2013-09 – 2014-05 · Neovascular Age-Related Macular Degeneration
What this study did
NCT01175395 · University of Illinois at Chicago
2010-09 – 2013-01 · Age-Related Macular Degeneration, Choroidal Neovascularization
What this study did
NCT01025232 · David M. Brown, M.D.
2009-12 – 2013-01 · Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration, Macular Degeneration, Wet Age-Related Macular Degeneration
What this study did
Other / comorbidity
NCT02859441 · National Eye Institute (NEI)
2017-01-23 – 2019-07-09 · Von Hippel-Lindau Syndrome
What this study did
NCT01003106 · Peter A Campochiaro, MD
2009-11 – 2015-04 · Retinal Vein Occlusion
What this study did
NCT01469156 · Southeast Retina Center, Georgia
2011-09 – 2015-02 · Polypoidal Choroidal Vasculopathy
What this study did
NCT02614937 · Ohr Pharmaceutical Inc.
2013-04 – 2014-12 · Retinal Vein Occlusion, Macular Edema
What this study did
NCT00661583 · University of Colorado, Denver
2008-04 – 2014-09 · Glaucoma
What this study did
NCT01884597 · Hawaii Pacific Health
2010-11 – 2014-08 · PCV, Polypoidal Choroidal Vasculopathy
What this study did
NCT01471691 · Hanscom, Thomas, M.D.
2011-11 – 2014-02 · Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
What this study did
NCT01248117 · Retina Consultants of Hawaii
2010-11 – 2013-02 · Polypoidal Choroidal Vasculopathy
What this study did
NCT00407355 · Peter A Campochiaro, MD
2006-01 – 2013-02 · Macular Edema, Retinal Vein Occlusion
What this study did
NCT01325181 · Jang Won Heo
2009-07 – 2012-09 · Chronic Central Serous Chorioretinopathy
What this study did
NCT01746563 · University of Sao Paulo
2011-05 – 2012-08 · Diabetic Retinopathy, Retinal Diseases, Eye Diseases, Diabetic Angiopathies, Vascular Diseases, Cardiovascular Diseases
What this study did
NCT01015495 · University of Illinois at Chicago
2009-12 – 2011-01 · Angioid Streaks
What this study did
NCT00470977 · Manhattan Eye, Ear & Throat Hospital
2007-05 – 2010-12 · Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy, Pseudoxanthoma Elasticum, Pathological Myopia, Multi-focal Choroiditis, Rubeosis Iridis, Von Hippel Lindau Disease, BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
What this study did
NCT00837330 · Southeast Retina Center, Georgia
2006-05 – 2010-12 · Polypoidal Choroidal Vasculopathy
What this study did
NCT00606138 · Rush University Medical Center
2008-01 – 2010-10 · Proliferative Diabetic Retinopathy
What this study did
NCT00955630 · Retina Associates of Kentucky
2009-08 – 2010-08 · Ocular Histoplasmosis Syndrome
What this study did
NCT00993525 · University of Sao Paulo
2008-09 – 2010-03 · Proliferative Diabetic Retinopathy
What this study did
NCT00841373 · Southern New England Retina Associates
2007-07 – 2010-01 · Retinal Ischemia
What this study did
NCT00498355 · University of California, San Francisco
2007-07 – 2009-12 · Uveitis, Cytoid Macular Edema
What this study did
NCT00727038 · University of Illinois at Chicago
2008-01-04 – 2009-05-15 · Glaucoma, New Onset Glaucoma, Neovascular Glaucoma, New Onset Neovascular Glaucoma
What this study did
Phase 1 (48)
Age-Related Macular Degeneration
NCT02543229 · Opthea Limited
2015-07 – 2017-09 · Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration, Neovascularization, Pathologic
What this study did
NCT00403156 · Vitreous -Retina- Macula Consultants of New York
started 2006-11 · Choroidal Neovascularization
What this study did
NCT00726466 · Vitreous -Retina- Macula Consultants of New York
started 2008-03 · Age Related Macular Degeneration, AMD, CNV
What this study did
NCT00395551 · Ophthalmic Consultants of Boston
2005-12 – 2009-06 · Choroidal Neovascularization
What this study did
NCT00500344 · Washington University School of Medicine
2007-07 – 2009-03 · Age-related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT06205979 · Sohag University
2023-12-12 – 2024-06-14 · Diabetic Macular Edema
What this study did
NCT06771271 · Hoffmann-La Roche
2019-07-22 – 2023-11-13 · Diabetic Macular Edema, Uveitic Macular Edema
What this study did
NCT02281292 · Alcon Research
2015-12 – 2017-06 · Diabetic Macular Edema
What this study did
NCT00676559 · Johns Hopkins University
2008-04 – 2010-04 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT02530918 · Daiichi Sankyo
2015-07 – 2018-01-02 · Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
What this study did
NCT02022540 · PanOptica, Inc.
2014-02 – 2016-05 · Age-Related Macular Degeneration (AMD)
What this study did
NCT00517010 · University of California, Davis
2007-05 – 2010-06 · Age-related Macular Degeneration
What this study did
Other / comorbidity
NCT05248334 · Tianjin Medical University Eye Hospital
2022-04-10 – 2024-12-30 · Diabetic Retinopathy, Postoperative Recurrent Vitreous Hemorrhage, Pars Plana Vitrectomy, Ranibizumab
What this study did
NCT04878835 · Universiti Sains Malaysia
2018-05-01 – 2020-04-30 · Patients With Primary Nasal Pterygium
What this study did
NCT02294656 · Soll Eye
2014-11 – 2018-09 · CYSTOID MACULAR EDEMA
What this study did
NCT00765921 · Massachusetts Eye and Ear Infirmary
2008-06 – 2016-09 · Choroidal Melanoma
What this study did
NCT01169909 · University of New Mexico
2010-08 – 2014-07 · Pterygium
What this study did
NCT00657202 · Massachusetts General Hospital
2008-03 – 2013-12 · Neurofibromatosis Type 1, Cutaneous Neurofibromas
What this study did
NCT01011374 · Retina Associates of Cleveland, Inc
2009-11 – 2013-11 · Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
What this study did
NCT00667472 · University of California, Irvine
2008-03 – 2013-11 · Port-Wine Stain
What this study did
NCT00826618 · University of Miami
2008-06 – 2013-09 · Uveitic Cystoid Macular Edema
What this study did
NCT01968486 · University of Campania Luigi Vanvitelli
2012-06 – 2013-07 · Myopia, Degenerative
What this study did
NCT01028248 · California Retina Consultants
2010-01 – 2013-06 · Central Retinal Vein Occlusion
What this study did
NCT01334879 · The New York Eye Cancer Center
2011-05 – 2012-11 · Radiation Retinopathy
What this study did
NCT00749021 · Clement K. Chan
2008-09 – 2012-08 · Retinal Pigment Epithelial Detachment
What this study did
NCT01225146 · David M. Brown, M.D.
2010-10 – 2012-08 · Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases
What this study did
NCT01406639 · University of California, San Diego
2011-07 – 2012-05 · Hereditary Hemorrhagic Telangiectasia (HHT), Nosebleeds
What this study did
NCT00769145 · University of Miami
2008-10 – 2012-03 · Corneal Neovascularization
What this study did
NCT01069341 · Bhagat, Neelakshi, M.D., M.P.H.
2007-07 – 2012-01 · Rubeosis Iridis, Proliferative Diabetic Retinopathy
What this study did
NCT00768963 · University of Miami
2008-10 – 2012-01 · Pterygium
What this study did
NCT00403039 · Vitreous -Retina- Macula Consultants of New York
2006-11 – 2011-12 · Retinal Vein Occlusion
What this study did
NCT00750399 · The New York Eye Cancer Center
2008-10 – 2011-09 · Radiation Retinopathy, Choroidal Melanoma
What this study did
NCT00685503 · National Eye Institute (NEI)
2008-05-21 – 2011-04-12 · Neovascularization
What this study did
NCT00685854 · National Eye Institute (NEI)
2008-05-21 – 2011-03-24 · Macular Telangiectasia
What this study did
NCT00406471 · Greater Houston Retina Research
2005-05 – 2011-01 · Ischemic Central Retinal Vein Occlusion
What this study did
NCT00406796 · California Retina Consultants
2006-01 – 2010-10 · Central Retinal Vein Occlusion
What this study did
NCT00681889 · Reza Dana, MD
2008-04 – 2010-09 · Corneal Neovascularization
What this study did
NCT00424710 · Hawaii Pacific Health
2007-01 – 2010-09 · Polypoidal Choroidal Vasculopathy
What this study did
NCT00456495 · The New York Eye Cancer Center
2007-03 – 2010-09 · Conjunctival Neoplasms
What this study did
NCT00363168 · Johns Hopkins University
2006-08 – 2009-05 · Choroidal Neovascularization
What this study did
NCT00561834 · University of Colorado, Denver
2007-11 – 2009-04 · Nonarteritic Anterior Ischemic Optic Neuropathy
What this study did
NCT00378196 · Johns Hopkins University
2006-09 – 2008-12 · Telangiectasia
What this study did
NCT00403325 · Vitreous -Retina- Macula Consultants of New York
started 2006-08 · Central Serous Chorioretinopathy
What this study did
NCT00570726 · The New York Eye & Ear Infirmary
2000-06 – 2007-11 · Glaucoma, Open-Angle, Failing Bleb Following Trabeculectomy
What this study did
NCT00457067 · National Eye Institute (NEI)
2007-03-27 – 2007-10-24 · Telangiectasia
What this study did
NCT00457145 · National Eye Institute (NEI)
2007-03-27 – 2007-10-24 · Telangiectasia
What this study did
NCT00089765 · National Eye Institute (NEI)
2004-08-10 – 2007-08-15 · Von Hippel-Lindau Syndrome
What this study did
Phase 4 (97)
Age-Related Macular Degeneration
NCT03056092 · Unity Health Toronto
2017-02-28 – 2024-02-28 · Age Related Macular Degeneration, Diabetic Macular Edema, Macular Edema, Retinal Vein Occlusion
What this study did
NCT04698850 · Faculty Hospital Kralovske Vinohrady
2021-01-04 – 2023-06 · Wet Macular Degeneration
What this study did
NCT02976194 · Pusan National University Hospital
2016-11-22 – 2020-01 · Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
What this study did
NCT02806752 · Aier School of Ophthalmology, Central South University
2017-01 – 2019-12 · Wet Macular Degeneration
What this study did
NCT02864472 · Seoul National University Hospital
2016-09 – 2019-01 · Age-related Macular Degeneration
What this study did
NCT01213667 · University of Cologne
2010-01 – 2017-12 · Macular Degeneration
What this study did
NCT02130024 · Novartis Pharmaceuticals
2014-04-11 – 2017-11-15 · Age-Related Macular Degeneration
What this study did
NCT01846273 · Novartis Pharmaceuticals
2013-08-07 – 2017-03-02 · Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
What this study did
NCT02140411 · Novartis Pharmaceuticals
2015-04-25 – 2016-12-21 · Retinal Vein Occlusion, Age Related Macular Degeneration
What this study did
NCT03393767 · Vista Klinik
2010-12 – 2016-12 · Choroidal Neovascularization, Age Related Macular Degeneration
What this study did
NCT02577107 · Novartis Pharmaceuticals
2016-01-13 – 2016-07-09 · Age-related Macular Degeneration
What this study did
NCT01319188 · Ural State Medical University
2010-06 – 2015-04 · Age-related Macular Degeneration, Coronary Artery Disease, Cerebrovascular Disorders
What this study did
NCT01127360 · Oslo University Hospital
2009-03 – 2014-08 · Exudative Age-related Macular Degeneration
What this study did
NCT03409250 · Vista Klinik
2011-06 – 2014-07 · Choroidal Neovascularization, Age Related Macular Degeneration
What this study did
NCT02060604 · Università degli Studi di Brescia
2012-12 – 2014-01 · Wet Macular Degeneration
What this study did
NCT00533520 · Brandon G. Busbee, MD
2007-09 – 2013-11 · Macular Degeneration, Choroidal Neovascularization
What this study did
NCT01831947 · Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
2010-04 – 2013-03 · Macular Degeneration
What this study did
NCT01810042 · Pusan National University Hospital
2010-10 – 2013-02 · Exudative Age-related Macular Degeneration
What this study did
NCT01464723 · University of California, San Diego
2008-05 – 2013-01 · Age-Related Macular Degeneration
What this study did
NCT01453920 · University Health Network, Toronto
2011-11 – 2012-07 · Age Related Macular Degeneration
What this study did
NCT01500915 · Institut de la Macula y la Retina
2010-11 – 2012-07 · Exudative Age-related Macular Degeneration
What this study did
NCT00473642 · Oklahoma State University Center for Health Sciences
2007-05 – 2010-04 · Age-Related Maculopathy, Choroidal Neovascularization
What this study did
NCT00504959 · Novartis
2007-07 – 2010-01 · Subfoveal Choroidal Neovascularization (CNV), Secondary to Age-related Macular Degeneration (AMD)
What this study did
NCT00680498 · Illinois Retina Associates
2007-02 – 2009-10 · Age-Related Macular Degeneration
What this study did
NCT00423189 · David M. Brown, M.D.
2007-01 – 2009-01 · Age-Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT07924072 · Benha University
2024-01-01 – 2025-01-01 · Diabetic Macular Edema
What this study did
NCT05861466 · Ain Shams University
2023-01-01 – 2024-11-24 · Diabetic Macular Edema
What this study did
NCT04991350 · Cairo University
2021-11-26 – 2022-11-01 · Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression
What this study did
NCT04464694 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2020-09-01 – 2022-06-01 · Proliferative Diabetic Retinopathy, Diabetic Macular Edema
What this study did
NCT03690947 · Beijing Hospital
2018-10-01 – 2021-09-30 · Diabetic Macular Edema
What this study did
NCT03759860 · CynosureLutronic
2018-01-08 – 2020-07-30 · Diabetic Macular Edema
What this study did
NCT04087746 · Minia University
2017-01 – 2019-06 · Diabetic Macular Edema
What this study did
NCT03340610 · Southeast Retina Center, Georgia
2015-06 – 2018-12-12 · Diabetic Macular Edema
What this study did
NCT02665689 · Prof. Dr. Antonia M. Joussen
2016-01-18 – 2018-09-07 · Visual Acuity Reduced Transiently, Macular Edema, Cystoid
What this study did
NCT03590444 · Hospital Hietzing
2017-04-02 – 2018-06-02 · Diabetic Retinal Edema
What this study did
NCT03458923 · Cairo University
2015-01 – 2018-06 · Diabetic Macular Edema
What this study did
NCT03097068 · Vitreo-Retinal Associates, Michigan
2017-04-19 – 2018-02-02 · Diabetic Macular Edema
What this study did
NCT02059772 · GWT-TUD GmbH
2014-04-30 – 2017-12-31 · Diabetic Macular Edema
What this study did
NCT02878681 · Novartis Pharmaceuticals
2016-09 – 2017-09 · Visual Impairment Due to Diabetic Macular Edema
What this study did
NCT02107131 · California Retina Consultants
2015-03-13 – 2017-05-15 · Diabetic Macular Edema
What this study did
NCT02684084 · North Toronto Eye Care Laser and Eye Specialists
2015-11 – 2016-12 · Diabetic Macular Edema
What this study did
NCT02258009 · Novartis Pharmaceuticals
2015-10 – 2016-10 · Visual Impairment Due to Diabetic Macular Edema
What this study did
NCT02646670 · Instituto de Olhos de Goiania
2015-07 – 2015-11 · Retinal Diseases
What this study did
NCT02055911 · Federal University of São Paulo
2014-03 – 2015-07 · Diabetic Macular Edema
What this study did
NCT00682539 · Medical University of Vienna
2007-10 – 2014-07 · Diabetic Macular Edema
What this study did
NCT01297569 · Novartis Pharmaceuticals
2011-01 – 2012-11 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT02321839 · Nagoya City University
2014-01 – 2019-03 · Neovascular Age-related Macular Degeneration
What this study did
NCT02634970 · Novartis Pharmaceuticals
2016-03 – 2017-12 · Wet Age-related Macular Degeneration (Wet AMD)
What this study did
NCT02843490 · Johannes Gutenberg University Mainz
2016-08-05 – 2017-11-09 · Neovascular Age-related Macular Degeneration
What this study did
Early phase / not applicable (46)
Age-Related Macular Degeneration
NCT02174211 · King's College Hospital NHS Trust
2014-06 – 2020-12 · Age Related Macular Degeneration
What this study did
NCT03038048 · Wills Eye
2017-01-27 – 2017-04-27 · Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
What this study did
NCT02328209 · Mie University
2014-06 – 2016-12 · Exudative Age-related Macular Degeneration
What this study did
NCT01521819 · Oraya Therapeutics, Inc.
2012-08 – 2014-08 · Retinal Pigment Epithelial Detachment With Vascularization, Age Related Macular Degeneration
What this study did
NCT01638858 · University of Luebeck
2011-10 – 2014-07 · Age-Related Macular Degeneration
What this study did
NCT01473251 · Vitreo-Retinal Associates, Michigan
2011-11 – 2014-04 · Exudative Macular Degeneration, Diabetic Macular Edema
What this study did
NCT01269151 · University of Luebeck
2010-10 – 2014-04 · Age-Related Macular Degeneration, Retinal Function
What this study did
NCT01626339 · University of Malaya
2012-04 – 2012-06 · Age Related Macular Degeneration
What this study did
NCT00455871 · Barnes Retina Institute
2007-04 – 2010-10 · Age-Related Macular Degeneration
What this study did
NCT00640640 · Sheba Medical Center
2007-08 – 2009-02 · Neovascular Age Related Macular Degeneration
What this study did
NCT00539734 · Prince of Songkla University
2007-08 – 2009-02 · Age-related Macular Degeneration
What this study did
NCT00379795 · Genentech, Inc.
2005-04 – 2008-09 · Choroidal Neovascularization, Age-related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT04601675 · He Eye Hospital
2020-10-31 – 2021-09-17 · Macular Edema
What this study did
NCT04332133 · Minia University
2016-12 – 2019-12 · Diabetic Macular Edema
What this study did
NCT03975088 · University of Alexandria
2017-01-01 – 2018-12-31 · Diabetic Macular Edema
What this study did
NCT04186702 · Ain Shams University
2014-09-10 – 2017-09-09 · Diabetes Mellitus, With Complications
What this study did
Wet Age-Related Macular Degeneration
NCT03944070 · Ophthalmica Eye Institute
2018-01-01 – 2020-01 · Wet Macular Degeneration, Cataract Extraction
What this study did
NCT01676506 · Russian Academy of Medical Sciences
2011-10 – 2015-10 · Age-Related Macular Degeneration
What this study did
NCT01363570 · McMaster University
2012-01 – 2014-10 · Age Related Macular Degeneration
What this study did
NCT01291121 · Yonsei University
2011-02 – 2013-06 · Neovascular Age-related Macular Degeneration
What this study did
Other / comorbidity
NCT07819253 · Aswan University
2023-07-01 – 2025-07-31 · Proliferative Diabetic Retinopathy (PDR)
What this study did
NCT07721298 · Ain Shams University
2021-09-10 – 2025-02-01 · Retinopathy of Prematurity (ROP)
What this study did
NCT06173245 · Egyptian Biomedical Research Network
2021-02-01 – 2023-02-01 · Subfoveal Choroidal Thickness, Intravitreal, Ranibizumab, Visual Acuity, Diabetic Retinopathy
What this study did
NCT05414149 · Peking University People's Hospital
2021-09-01 – 2022-05-31 · Proliferative Diabetic Retinopathy
What this study did
NCT01968616 · Kyoto University, Graduate School of Medicine
2013-09 – 2019-09 · Macular Edema Due to BRVO/CRVO
What this study did
NCT03054766 · Beijing Hospital
2017-02-14 – 2019-01-28 · Branch Retinal Vein Occlusion, Ranibizumab, Laser Photocoagulation
What this study did
NCT03115255 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2017-05-01 – 2018-06-30 · Infant, Premature, Diseases
What this study did
NCT02857491 · Sun Yat-sen University
2014-07 – 2017-09-30 · Proliferative Diabetic Retinopathy
What this study did
NCT02144662 · St. Marianna University School of Medicine
2014-03 – 2017-04-30 · Researcher-Subject Relations
What this study did
NCT02091505 · Mie University
2013-12 – 2016-05 · Central Retinal Vein Occlusion
What this study did
NCT02158624 · Kyushu University
2013-12 – 2015-12 · Visual Disorder Due to Age-related Macula Degeneration
What this study did
NCT02169648 · Tokyo Medical University
2013-12 – 2015-12 · Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
What this study did
NCT01428388 · Barnes Retina Institute
2011-09 – 2015-12 · Retinal Vein Occlusion, Macular Edema
What this study did
NCT03459144 · Sun Yat-sen University
2012-12-01 – 2015-07-30 · Polypoidal Choroidal Vasculopathy
What this study did
NCT01581151 · Brian Burke, MPH
2011-09 – 2015-06 · Retinal Vein Occlusion
What this study did
NCT00892398 · Maisonneuve-Rosemont Hospital
2009-03 – 2014-03 · Glaucoma
What this study did
NCT02164604 · Kantonsspital Aarau
2011-01 – 2013-10 · Retinopathy of Prematurity
What this study did
NCT01238393 · Queen's University
2010-11 – 2012-01 · Epiretinal Membrane
What this study did
NCT01370135 · University of Luebeck
2008-11 – 2011-07 · Neovascular Glaucoma, Rubeosis
What this study did
NCT00618644 · Kresge Eye Institute
2010-01 – 2011-06 · Sickle Cell Anemia, Retinopathy
What this study did
NCT01360151 · Seoul St. Mary's Hospital
2011-02 – 2011-05 · Polypoidal Choroidal Vasculopathy
What this study did
NCT00644280 · University of California, San Francisco
2008-04 – 2011-01 · Glaucoma
What this study did
NCT01256632 · Vision Research Foundation
2007-10 – 2010-10 · Choroidal Neovascularization
What this study did
NCT00562406 · Klinikum Ludwigshafen
2007-11 – 2010-09 · Macular Edema
What this study did
NCT01442064 · Genentech, Inc.
2008-07 – 2010-07 · Macular Edema, Retinal Vein Occlusion
What this study did
Used as active comparator (74)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (33)
Age-Related Macular Degeneration
NCT06305416 · Incepta Pharmaceuticals Ltd
2024-03-30 – 2026-05-17 · Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Macular Degeneration, Retinal Disease, Retinal Degeneration
What this study did
NCT04740671 · Shanghai Henlius Biotech
2021-07-01 – 2024-12-31 · Age Related Macular Degeneration
What this study did
NCT05003245 · Shanghai Henlius Biotech
2021-11-01 – 2024-05-07 · Age Related Macular Degeneration
What this study did
NCT01170767 · Hospices Civils de Lyon
2009-06 – 2012-12 · Age Related Macular Degeneration
What this study did
NCT00454389 · NeoVista
2007-04 – 2012-08 · Macular Degeneration
What this study did
NCT00557791 · OPKO Health, Inc.
2009-11 – 2012-07 · Age Related Macular Degeneration
What this study did
NCT00559715 · Klinikum Bremen-Mitte, gGmbH
2008-08 – 2010-08 · Age-Related Neovascular Macular Degeneration
What this study did
NCT00436553 · Novartis
2007-02 – 2009-10 · Macular Degeneration, Choroidal Neovascularization
What this study did
NCT00499590 · OPKO Health, Inc.
2007-08 – 2009-05 · Macular Degeneration
What this study did
NCT00429962 · University Hospital, Basel, Switzerland
2006-07 – 2008-06 · Choroidal Neovascularization, Age-Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT07515079 · Bio-Thera Solutions
2024-10-09 – 2027-04-30 · Diabetic Macular Edema (DME)
What this study did
NCT05217680 · Laboratorios Sophia S.A de C.V.
2021-05-24 – 2025-11-25 · Diabetic Macular Edema
What this study did
NCT01627249 · Jaeb Center for Health Research
2012-08 – 2019-04-18 · Diabetic Macular Edema
What this study did
NCT00545870 · Ursula Schmidt-Erfurth, M.D.
2008-06 – 2013-04 · Diabetic Retinopathy, Diabetic Macular Edema, Proliferative Diabetic Retinopathy
What this study did
Wet Age-Related Macular Degeneration
NCT07816289 · Ollin Biosciences, Inc.
2026-10-15 – 2029-12-15 · Wet Age-related Macular Degeneration
What this study did
NCT06952452 · Parc de Salut Mar
2022-11-18 – 2026-05-28 · Wet Age-related Macular Degeneration
What this study did
NCT05480293 · Sinocelltech Ltd.
2023-02-14 – 2025-08-31 · Wet Age-related Macular Degeneration
What this study did
NCT05439629 · Bio-Thera Solutions
2022-07-07 – 2025-04-22 · Neovascular (Wet) Age-related Macular Degeneration
What this study did
NCT05461339 · BioDlink Biopharm Co., Ltd.
2022-06-28 – 2025-02 · Neovascular Age-related Macular Degeneration
What this study did
NCT06190093 · Outlook Therapeutics, Inc.
2024-01-24 – 2024-12-05 · Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
What this study did
NCT07389577 · Jecho Biopharmaceuticals Co., Ltd.
2022-03-01 – 2024-09-23 · Wet Age-related Macular Degeneration
What this study did
NCT04690556 · Lupin Ltd.
2020-09-14 – 2024-05-31 · Neovascular Age-related Macular Degeneration
What this study did
NCT03834753 · Outlook Therapeutics, Inc.
2019-06-25 – 2021-07-08 · Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
What this study did
NCT04857177 · Chong Kun Dang Pharmaceutical
2018-10-19 – 2021-03-17 · Neovascular(Wet) Age Related Macular Degeneration
What this study did
NCT03844074 · Outlook Therapeutics, Inc.
2018-10-01 – 2020-08-13 · Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
What this study did
NCT02462928 · Allergan
2015-06-25 – 2019-06-19 · Macular Degeneration
What this study did
NCT02462486 · Allergan
2015-06-25 – 2019-06-06 · Macular Degeneration
What this study did
NCT02036723 · Biocad
est. completion 2016-03 · Wet Age-related Macular Degeneration
What this study did
NCT00637377 · Bayer
2008-04 – 2011-08 · Macular Degeneration
What this study did
NCT00509795 · Regeneron Pharmaceuticals
2007-08 – 2011-07 · Macular Degeneration
What this study did
Other / comorbidity
NCT06176352 · Hoffmann-La Roche
2024-03-06 – 2026-05-22 · Choroidal Neovascularization Secondary to Pathologic Myopia
What this study did
NCT05520177 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2022-12-27 – 2024-09-23 · Branch Retinal Vein Occlusion
What this study did
Phase 2/3 (4)
Diabetic Macular Edema
NCT06957080 · EyeBiotech Ltd.
2025-04-16 – 2028-01-11 · Diabetic Macular Edema (DME)
What this study did
NCT06571045 · EyeBiotech Ltd.
2024-08-07 – 2027-08-14 · Diabetic Macular Edema (DME)
What this study did
Wet Age-Related Macular Degeneration
NCT04704921 · AbbVie
2020-12-29 – 2027-11 · AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
What this study did
NCT05297292 · Mabwell (Shanghai) Bioscience Co., Ltd.
2021-05-07 – 2024-06-30 · Wet Age-related Macular Degeneration
What this study did
Phase 2 (26)
Age-Related Macular Degeneration
NCT03038880 · Hoffmann-La Roche
2017-01-27 – 2018-03-29 · Neovascularization, Choroidal, Macular Degeneration, Age-Related
What this study did
NCT02484690 · Hoffmann-La Roche
2015-08-11 – 2017-09-26 · Choroidal Neovascularization
What this study did
NCT02358889 · Iconic Therapeutics, Inc.
2015-02 – 2016-09 · Choroidal Neovascularization, Age-related Macular Degeneration
What this study did
NCT01162746 · Medical University of Vienna
2011-10 – 2015-12 · Age-Related Macular Degeneration, Neovascularization, Choroidal
What this study did
NCT02222207 · Bayer
2014-10 – 2015-06 · Macular Degeneration
What this study did
NCT01849692 · Alcon Research
2013-06 – 2015-01 · Exudative Age-Related Macular Degeneration
What this study did
NCT01397409 · Allergan
2011-09-01 – 2014-04-30 · Age-related Macular Degeneration
What this study did
NCT01157065 · Alcon Research
2011-06 – 2012-04 · Exudative Age-Related Macular Degeneration
What this study did
NCT00395057 · Allergan
2007-01 – 2009-02 · Choroid Neovascularization, Age-Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT05151731 · Hoffmann-La Roche
2021-12-31 – 2025-04-21 · Diabetic Macular Edema
What this study did
NCT03927690 · Novartis Pharmaceuticals
2019-05-24 – 2022-08-31 · Diabetic Macular Edema
What this study did
NCT02699450 · Hoffmann-La Roche
2016-04-27 – 2017-12-14 · Diabetic Macular Edema
What this study did
NCT02511067 · University of Nebraska
2016-10-01 – 2016-10-05 · Diabetic Macular Edema
What this study did
NCT02302079 · Astellas Pharma Europe B.V.
2015-01-12 – 2016-08-12 · Diabetes Mellitus, Diabetic Macular Edema
What this study did
NCT02186119 · Allergan
2014-07 – 2015-06 · Macular Edema
What this study did
NCT02050828 · Aerpio Therapeutics
2014-01 – 2015-05 · Diabetic Macular Edema (DME)
What this study did
NCT01492400 · Allergan
2012-03-09 – 2014-02-13 · Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT04514653 · AbbVie
2020-08-25 – 2027-02 · Neovascular Age-Related Macular Degeneration (nAMD)
What this study did
NCT02181504 · Allergan
2014-09 – 2015-12 · Macular Degeneration
What this study did
NCT02181517 · Allergan
2014-07 – 2015-03 · Macular Degeneration
What this study did
NCT01134055 · GlaxoSmithKline
2010-06-01 – 2012-10-01 · Macular Degeneration
What this study did
NCT00992563 · Alcon Research
2010-06 – 2011-05 · Age Related Macular Degeneration
What this study did
NCT00805233 · Oregon Health and Science University
2008-12 – 2010-09 · Age-Related Macular Degeneration
What this study did
NCT00857259 · Novartis Pharmaceuticals
2009-02 – 2010-07 · Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
What this study did
Other / comorbidity
NCT04922151 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2021-06-04 – 2023-07-31 · Pathological Myopic Choroidal Neovascularization
What this study did
Phase 1/2 (5)
Age-Related Macular Degeneration
NCT01494805 · Lions Eye Institute, Perth, Western Australia
2011-12 – 2017-08 · Macular Degeneration, Age-related Maculopathies, Age-related Maculopathy, Maculopathies,Age-related, Maculopathy,Age-related, Retinal Degeneration, Retinal Neovascularization, Eye Diseases
What this study did
NCT02121353 · Pfenex, Inc
2013-11 – 2016-01 · Age Related Macular Degeneration (AMD)
What this study did
NCT00793923 · Subhransu K. Ray, M.D., Ph.D.
2008-01 – 2012-12 · Exudative Age-Related Macular Degeneration
What this study did
Wet Age-Related Macular Degeneration
NCT02398500 · Alcon Research
2015-07-22 – 2016-05-20 · Age-related Macular Degeneration (AMD)
What this study did
NCT01304693 · Alcon Research
2010-10 – 2013-03 · Exudative Age-Related Macular Degeneration
What this study did
Phase 1 (2)
Wet Age-Related Macular Degeneration
NCT04884399 · Shanghai Biomabs Pharmaceutical Co., Ltd.
2021-06-03 – 2022-12-22 · Wet Age-related Macular Degeneration
What this study did
NCT03312283 · Qilu Pharmaceutical Co., Ltd.
2017-12-20 – 2019-04-02 · Wet Age-related Macular Degeneration
What this study did
Phase 4 (3)
Diabetic Macular Edema
NCT03832179 · Bay Area Retina Associates
2018-11-15 – 2024-03-30 · Diabetic Macular Edema, Cataract
What this study did
NCT04089605 · Far Eastern Memorial Hospital
2017-06-01 – 2019-04-30 · Diabetic Macular Edema
What this study did
Other / comorbidity
NCT03999125 · Sudhalkar Eye Hospital
2019-06-25 – 2023-06-24 · Clinically Significant Macular Edema Due to Diabetes Mellitus
What this study did
Early phase / not applicable (1)
Diabetic Macular Edema
NCT07520045 · Osijek University Hospital
2026-03-12 – 2027-06-01 · Diabetic Retinopathy (DR), Diabetic Macular Edema (DME)
What this study did
Appears in other studies (27)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (4)
Age-Related Macular Degeneration
NCT01944839 · Ophthotech Corporation
2013-08 – 2016-12 · Age-Related Macular Degeneration
What this study did
NCT01940900 · Ophthotech Corporation
2013-08 – 2016-12 · Age-Related Macular Degeneration
What this study did
Wet Age-Related Macular Degeneration
NCT02727881 · Ohr Pharmaceutical Inc.
2016-04-12 – 2017-12 · Age-related Macular Degeneration
What this study did
Other / comorbidity
NCT04444492 · University of Giessen
2020-08-25 – 2027-11-30 · Central Retinal Vein Occlusion With Macular Edema
What this study did
Phase 2/3 (2)
Age-Related Macular Degeneration
NCT00433017 · Novartis
2007-05 – 2009-07 · Macular Degeneration, Choroidal Neovascularization
What this study did
Wet Age-Related Macular Degeneration
NCT01835067 · King's College Hospital NHS Trust
2014-09 – 2019-12 · Exudative Macular Degeneration, Retinal Hemorrhage
What this study did
Phase 2 (10)
Age-Related Macular Degeneration
NCT03725501 · AngioLab, Inc.
2018-12-07 – 2021-06-22 · Age-Related Macular Degeneration
What this study did
NCT00511706 · Allergan
2007-11-01 – 2009-03-01 · Choroidal Neovascularization, Age-Related Maculopathy
What this study did
Diabetic Macular Edema
NCT03161652 · Carmen Clapp
2017-05-24 – 2027-06 · Diabetic Macular Edema, Diabetic Retinopathy
What this study did
NCT05151744 · Hoffmann-La Roche
2021-12-17 – 2024-10-01 · Diabetic Macular Edema
What this study did
NCT01945866 · Jaeb Center for Health Research
2014-02 – 2017-06-05 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT05210803 · AbbVie
2021-12-20 – 2031-07 · Neovascular Age-Related Macular Degeneration (nAMD)
What this study did
NCT03345082 · Opthea Limited
2017-11-06 – 2019-05-14 · Neovascular Age-related Macular Degeneration
What this study did
NCT02355028 · Alcon, a Novartis Company
2015-03-03 – 2016-10-18 · Exudative Age-Related Macular Degeneration
What this study did
Other / comorbidity
NCT03499223 · Oxurion
2018-04-20 – 2019-07-18 · Diabetes Mellitus, Diabetic Retinopathy, Macular Edema
What this study did
NCT01247220 · Retina Associates of Florida, P.A.
2010-11 – 2014-05 · Macular Edema, Branch Retinal Vein Occlusion
What this study did
Phase 1/2 (1)
Diabetic Macular Edema
NCT01552408 · David M. Brown, M.D.
2012-03 – 2017-05-18 · Diabetic Macular Edema
What this study did
Phase 4 (7)
Age-Related Macular Degeneration
NCT04075136 · Wake Forest University Health Sciences
2023-03-30 – 2024-12 · Exudative Age Related Macular Degeneration
What this study did
NCT01006538 · King's College Hospital NHS Trust
2009-11 – 2016-12 · Macular Degeneration
What this study did
Diabetic Macular Edema
NCT02462304 · The University of Hong Kong
2015-06 – 2017-12 · Diabetic Macula Edema
What this study did
Other / comorbidity
NCT02953938 · Novartis Pharmaceuticals
2016-12-15 – 2018-12-28 · Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
What this study did
NCT02522897 · PD. Dr. med. Armin Wolf
2015-08 – 2018-01 · Central Retinal Vein Occlusion With Macular Edema
What this study did
NCT03261635 · Università degli Studi di Brescia
2016-01-07 – 2017-07-25 · Macular Edema
What this study did
Early phase / not applicable (3)
Age-Related Macular Degeneration
NCT00709657 · Medical University of Vienna
2008-03 – 2011-11 · Macular Degeneration, Regional Blood Flow, Vascular Endothelial Growth Factor
What this study did
Wet Age-Related Macular Degeneration
Other / comorbidity
NCT02207712 · PolyPhotonix Medical
2014-11 – 2023-08 · Diabetic Macular Oedema
What this study did

Competitive landscape

This mechanism is crowded: 38 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Age-Related Macular Degeneration: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ranibizumab (Lucentis): this drugApprovedAntibody fragmentVEGF-APartial signal
NCT00056836: Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham.
Aflibercept (Eylea)ApprovedProtein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Reliable signal
NCT00509795: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0)
NCT00637377: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (At week 52): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 95.62% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 96.27% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 95.56% vs Ranibizumab 0.5mg Q4 94.42%
Aflibercept-Abzv (Enzeevu)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)ApprovedProtein / enzyme therapeuticVEGF-AReliable signal
NCT04270747: Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97)
Aflibercept-Boav (Eydenzelt)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Avacincaptad Pegol (Izervay)ApprovedRNA AptamerComplement C5Reliable signal
NCT04435366: 12-month geographic-atrophy growth: 0.336 vs 0.392 mm/year for avacincaptad pegol vs sham; difference 0.056 mm/year (95% CI 0.016 to 0.096; p=0.0064). 24-month geographic-atrophy growth: 2.23 vs 2.59 mm²/year for monthly avacincaptad pegol vs sham; difference 0.362 mm²/year (95% CI 0.066 to 0.657; p=0.0165).
NCT02686658: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence (Baseline and 12 months): Zimura 2 mg [Part 1 & Part 2 Combined] 0.292 millimeters (mm) (Standard Error 0.077) | Zimura 4 mg [Part 2] 0.321 millimeters (mm) (Standard Error 0.074) vs Sham [Part 1 & Part 2 Combined] 0.402 millimeters (mm) (Standard Error 0.075) | Sham [Part 2] 0.444 millimeters (mm) (Standard Error 0.072)
BAT1706 (Avzivi)
Approved(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
Bevacizumab
Approved(overall)
Monoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitor
Partial signal(overall)
No reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)
Approved(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Brolucizumab-DbllApprovedAntibody fragmentVEGF-AWeak signalNo reviewed efficacy summary in this indication
FaricimabApprovedMultispecific antibodyAngiopoietin-2 / VEGF-APartial signal
NCT03823287: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 5.8 vs 5.1 letters, adjusted mean difference 0.7 (95% CI -1.1 to 2.5); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
NCT03823300: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 6.6 vs 6.6 letters, adjusted mean difference 0.0 (95% CI -1.7 to 1.8); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
Jobevne (bevacizumab-Nwgd)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Pegcetacoplan Ophthalmic (Syfovre)ApprovedPeptideComplement C3, Complement C3 / C3bReliable signal
NCT03525613: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.5579 mm^2 (Standard Error 0.0835) | Pegcetacoplan EOM 1.6512 mm^2 (Standard Error 0.08118) vs Sham Pooled 1.9692 mm^2 (Standard Error 0.08218)
NCT03525600: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.7344 mm^2 (Standard Error 0.07924) | Pegcetacoplan EOM 1.7563 mm^2 (Standard Error 0.07446) vs Sham Pooled 1.964 mm^2 (Standard Error 0.09592) missed
Ranibizumab-Eqrn (Cimerli)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Nuna (Byooviz)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Vegzelma (bevacizumab-Adcd)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Verteporfin (Visudyne)ApprovedSmall moleculeBenzoporphyrin-derivative photosensitizer for photodynamic therapyPartial signal
NCT00436553: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 (Baseline and Month 12): Verteporfin SF + Ranibizumab — Baseline: 53.7 Letters (Standard Deviation 13.52); Month 12: 59 Letters (Standard Deviation 17.47); Change from baseline: 5.3 Letters (Standard Deviation 15.66) | Verteporfin RF + Ranibizumab — Baseline: 54.6 Letters (Standard Deviation 12.78); Month 12: 59 Letters (Standard Deviation 18.03); Change from baseline: 4.4 Letters (Standard Deviation 15.47) vs Ranibizumab Monotherapy — Baseline: 54.8 Letters (Standard Deviation 13.55); Month 12: 63 Letters (Standard Deviation 18.88); Change from baseline: 8.1 Letters (Standard Deviation 15.09) missed
NCT00121407: VIO trial, 24-month primary endpoint: 47% of verteporfin-PDT patients vs 53% of placebo patients lost ≥15 letters (not significant); source states n=384 vs task record's 364, but sponsor/design/QLT-era details match this trial (2:1 randomization, occult CNV, no classic component). missed
Zirabev (bevacizumab-Bvzr)
Approved(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Axitinib Intravitreal Implant (OTX-TKI)Phase 3Small moleculeVEGF receptors + PDGF receptorsPartial signal
NCT06223958: Superiority primary endpoint at week 36: 74.1% with AXPAXLI vs 55.8% with aflibercept 2 mg lost fewer than 15 ETDRS letters (2026-02-17).
BAT5906Phase 3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
CemdisiranPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
CKD-701 (Lucenbies)Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT04857177: Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%).
HD204
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
HLX04 (Hanbeitai)
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
HLX04-OPhase 3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
IBI305
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
LY01008
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ximluci)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RC28-EPhase 3Protein / enzyme therapeuticVEGF-A / FGF-2 (dual blockade)Partial signal
NCT04270669: Mean BCVA improvement from baseline at week 48: 6.1 ± 8.3 letters (0.5 mg), 9.9 ± 10.7 letters (1.0 mg), 7.6 ± 9.4 letters (2.0 mg)
Surabgene LomparvovecPhase 3Gene therapy / editingVEGF-AWeak signal
NCT04832724: Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0
Tabirafusp TedromerPhase 3Multispecific antibodyVEGF + IL-6Partial signal
NCT06556368: Primary endpoint: tabirafusp tedromer non-inferior to aflibercept on vision (p=0.0036); anatomical key secondary endpoint p<0.0001 (DAYBREAK, 2026-09-28).
Tarcocimab TedromerPhase 3Monoclonal antibodyVEGF-APartial signal
NCT04964089: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76)
NCT06556368: Primary endpoint, BCVA: met (p=0.0007) (Kodiak topline, 2026-09-28).
VonaprumentPhase 3Antibody fragmentComplement C1qPartial signal
NCT04656561: GA lesion growth vs sham at 12 months: 6.2% reduction monthly (p=0.526), 1.3% every-other-month (p=0.896), 3.7% pooled (p=0.673); primary endpoint not statistically significant. missed
MW02Phase 2/3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
BI 1584862Phase 2——not yet gradedNo reviewed efficacy summary in this indication
BI 771716Phase 2Antibody fragment—Weak signalFeatured results are safety only in this race
Iptacopan (Fabhalta)Phase 2Small moleculeComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
ABBV-6628Phase 1/2Antibody fragmentComplement C5not yet gradedNo reviewed efficacy summary in this indication
SAR402663Phase 1/2Gene therapy / editingVEGFnot yet gradedNo reviewed efficacy summary in this indication
SAR446597Phase 1/2Gene therapy / editingComplement C1s + Factor Bbnot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rimmyrah)Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Afiveg)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eyluxvi)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Mynzepli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Vgenfli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ranivisio)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rexatilux)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LazucirnonDiscontinuedSmall moleculeCCR3Partial signal
NCT04331730: Mean change in BCVA (ETDRS letters) from baseline to Week 36: AKST4290 800 mg + aflibercept +10.4 (SD 10.26, n=36), AKST4290 1600 mg + aflibercept +6.7 (SD 7.89, n=35), placebo + aflibercept +13.7 (SD 7.60, n=36); no between-group analysis posted (CT.gov posted results).
Telbermin
Discontinued
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.